TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25643246

Group type: EXPERIMENTAL
Intervention: Epidural (EPI) with well-functioning catheters
Number of subjects: 55

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with intravenous narcotics
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Epidural (EPI) with failed placements
Number of subjects: 55
Study: 25597506

Group type: EXPERIMENTAL
Intervention: Target temperature management (TTM) at 33 °C for 24h
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Target temperature management (TTM) at 36 °C for 24h
Number of subjects: 950

Group type: COMPARATOR
Intervention: Age groups comparison
Number of subjects: 950
Study: 22998533

Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/day for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (usual diet without flaxseed)
Number of subjects: 30
Study: 21647656

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18379534

Group type: EXPERIMENTAL
Intervention: Conventional PD fluid (1.36%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conventional PD fluid (3.86%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Biocompatible PD fluid (1.36%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Biocompatible PD fluid (3.86%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.86% glucose-containing fluid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.36% glucose-containing fluid
Number of subjects: 10
Study: 16670153

Group type: EXPERIMENTAL
Intervention: Endurance exercise training combined with dietary intervention (EX + DIET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary intervention without endurance exercise training (DIET)
Number of subjects: 0
Study: 12784341

Group type: EXPERIMENTAL
Intervention: DepoCyt
Number of subjects: 61

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 61
Study: 11517848

Group type: EXPERIMENTAL
Intervention: Supportive nursing intervention over 16 weeks (9 contacts: 5 in person, 4 by telephone)
Number of subjects: 125
Study: 9113256

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg orally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1396829

Group type: EXPERIMENTAL
Intervention: 51Cr EDTA elimination
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 30

Group type: COMPARATOR
Intervention: 51Cr EDTA elimination with captopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inulin clearance with captopril
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction group
Number of subjects: 30
Study: 4061896

Group type: EXPERIMENTAL
Intervention: Thiopental (2.5%) administered at doses of 2, 3, 4, 5, 6, 7, or 8 mg/kg
Number of subjects: 0
Study: 31204610

Group type: EXPERIMENTAL
Intervention: Active peer modeling intervention, including exercise prescription and information
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention control group (ACG) receiving general health information
Number of subjects: 50
Study: 30721637

Group type: EXPERIMENTAL
Intervention: 5-day high-fat overfeeding diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline TCF7L2 expression in mature adipose tissue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adipogenesis in isolated preadipocytes
Number of subjects: 40
Study: 29234038

Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfate (STS) injection (80 mg, once daily for 14 consecutive days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 70
Study: 26334924

Group type: EXPERIMENTAL
Intervention: Randomized Accelerated Maximum Likelihood (RAxML)
Number of subjects: 0
Study: 23625305

Group type: EXPERIMENTAL
Intervention: Cornus mas L. supplementation (50 g twice a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 40
Study: 21367399

Group type: EXPERIMENTAL
Intervention: Lumbar disk prosthesis surgery with metal on metal lumbar disk prosthesis and postoperative rehabilitation program
Number of subjects: 20
Study: 19212897

Group type: EXPERIMENTAL
Intervention: Physiotherapy for a minimum of 80 hours during the first year
Number of subjects: 75

Group type: COMPARATOR
Intervention: Self-initiated exercise (no specific therapy recommended)
Number of subjects: 75
Study: 17189955

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 12499180

Group type: EXPERIMENTAL
Intervention: EFV with NFV, IDV, SQV, or placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Higher adherence scores
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EFV in NNRTI-naive patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: EFV in NNRTI-experienced patients
Number of subjects: 139
Study: 10582503

Group type: EXPERIMENTAL
Intervention: Downward-tilting (DT) keyboard tray
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional keyboard on a desk
Number of subjects: 38
Study: 8559383

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 1925456

Group type: EXPERIMENTAL
Intervention: Jogging (2 hours/week for 4 months)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no jogging)
Number of subjects: 94
Study: 7081139

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette‐Guerin (BCG) adjuvant immunotherapy plus conventional therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 33
Study: 6365474

Group type: EXPERIMENTAL
Intervention: Diprolene ointment 0.05 percent (betamethasone dipropionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dermovate ointment 0.05 percent (clobetasone propionate) applied topically at a fixed dose of 7 gm/day for 14 days (Study 1) or 21 days (Study 2)
Number of subjects: 81
Study: 31296936

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation (50 µg per day)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Iron deficiency anaemia (IDA)
Number of subjects: 366
Study: 28381133

Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 76
Study: 26686960

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day)
Number of subjects: 1193
Study: 24498858

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 394

Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 394
Study: 22541245

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (320/9 μg twice-daily)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Budesonide pMDI (320 μg twice-daily)
Number of subjects: 742
Study: 19548011

Group type: EXPERIMENTAL
Intervention: Oral‐B Professional Care 8500 (PC 8500)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral‐B CrossAction Vitalizer (CAV)
Number of subjects: 66
Study: 18689569

Group type: EXPERIMENTAL
Intervention: Walnut-enriched restructured meat products
Number of subjects: 25
Study: 15870046

Group type: EXPERIMENTAL
Intervention: Embol‐X intraaortic filter
Number of subjects: 2297
Study: 12932245

Group type: EXPERIMENTAL
Intervention: PTH (1-34)
Number of subjects: 15
Study: 11195901

Group type: EXPERIMENTAL
Intervention: Electrical sacral nerve stimulation (SNS)
Number of subjects: 30
Study: 8981554

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1524321

Group type: EXPERIMENTAL
Intervention: Continuous oscillation therapy on the Kinetic Treatment Table
Number of subjects: 30

Group type: COMPARATOR
Intervention: No continuous oscillation therapy (Control)
Number of subjects: 30
Study: 6360704

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.6 mg, pressurized aerosol)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol (1.0 mg, pressurized aerosol)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.6 mg, dry powder)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol (1.0 mg, dry powder)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31125468

Group type: EXPERIMENTAL
Intervention: High-intensity small-sided real football games (SRF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moderate-intensity small-sided walking football games (SWF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Resting (RF)
Number of subjects: 81
Study: 29907864

Group type: EXPERIMENTAL
Intervention: Urinary metabolome analysis post TURBT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metabolomic profiling
Number of subjects: 0
Study: 27439509

Group type: EXPERIMENTAL
Intervention: ARDSnet + OLC (Open Lung Concept)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ARDSnet-24h
Number of subjects: 15

Group type: COMPARATOR
Intervention: ARDSnet-48h
Number of subjects: 15
Study: 24988955

Group type: EXPERIMENTAL
Intervention: Recombinant IL-2
Number of subjects: 40
Study: 22075112

Group type: EXPERIMENTAL
Intervention: Wording approach 1: 'we recommend', 'we suggest'
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Wording approach 2: 'clinicians should', 'clinicians might'
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Wording approach 3: 'we recommend', 'we conditionally recommend'
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Strong recommendations
Number of subjects: 341
Study: 20450503

Group type: EXPERIMENTAL
Intervention: Bipolar cautery with 0.9% normal saline irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monopolar cautery with 1.5% glycine irrigation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Bipolar and Monopolar)
Number of subjects: 0
Study: 17997261

Group type: EXPERIMENTAL
Intervention: Healthcare professional goal setting (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient goal setting (Group A)
Number of subjects: 0
Study: 16156463

Group type: EXPERIMENTAL
Intervention: Mobile Bearing (MB) design
Number of subjects: 42

Group type: COMPARATOR
Intervention: Posterior Stabilized (PS) design
Number of subjects: 42
Study: 12195113

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 120-139 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 140-159 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) categories of 159 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 70-79 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 80-89 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) ranges of 89 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) ranges from 54-67 mmHg
Number of subjects: 2939

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) ranges from 67 mmHg
Number of subjects: 2939
Study: 10618931

Group type: EXPERIMENTAL
Intervention: 0.1 MAC of sevoflurane
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (without sevoflurane)
Number of subjects: 8
Study: 8557010

Group type: EXPERIMENTAL
Intervention: 0.6 mg kg‐1 rocuronium (2 x ED95)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.06 mg kg‐1 priming dose followed by 0.24 mg kg‐1 rocuronium
Number of subjects: 30
Study: 1683148

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 53
Study: 7019803

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31970939

Group type: COMPARATOR
Intervention: TAC-302 (100 to 1200 mg single dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAC-302 (400 mg single dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAC-302 (100, 200, or 400 mg multiple doses for 5 days, twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAC-302
Number of subjects: 96
Study: 30838446

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group L40)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg (Group L20)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 0
Study: 28817744

Group type: EXPERIMENTAL
Intervention: Oral voriconazole (dosage not specified) and topical voriconazole, 1%
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Topical natamycin, 5% (added after 39 participants enrolled)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Geometric mean of the infiltrate (increase by 1 mm)
Number of subjects: 240
Study: 25921978

Group type: EXPERIMENTAL
Intervention: Proactive coping (measured using the Utrecht Proactive Coping Competence scale - UPCC)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-efficacy (measured using the General Self‐Efficacy Scale - GSES)
Number of subjects: 112
Study: 22836860

Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no somatostatin)
Number of subjects: 67
Study: 21071588

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 0.5 l/day, containing ∼6.2 mmol of NO(3)(‐)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PL) 0.5 l/day, containing ∼0.003 mmol of NO(3)(‐)
Number of subjects: 9
Study: 19786904

Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed (Cis/Pem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel/bevacizumab (Carb/Pac/Bev)
Number of subjects: 0
Study: 16421114

Group type: EXPERIMENTAL
Intervention: Volume of periventricular white matter hyperintensities (PVWMH) at baseline
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Progression in volume of periventricular white matter hyperintensities (PVWMH)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Presence or progression of deep white matter hyperintensities (DWMH)
Number of subjects: 554
Study: 15248068

Group type: EXPERIMENTAL
Intervention: Treadmill running (R)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cycle ergometry (R)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Treadmill running (C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cycle ergometry (C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Treadmill running (T)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cycle ergometry (T)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Treadmill running (U)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cycle ergometry (U)
Number of subjects: 36
Study: 11371408

Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill walking in patients with CHF
Number of subjects: 8

Group type: COMPARATOR
Intervention: Exhaustive treadmill walking in healthy subjects
Number of subjects: 8
Study: 9062599

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 1 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 2 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 2.89 mg/kg
Number of subjects: 60
Study: 8376436

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine injection into the wound (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: None (Control group, n = 30)
Number of subjects: 60
Study: 3740650

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 2 mg by inhalation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 4 mg by inhalation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine sulfate 6 mg by inhalation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atropine free base 1.67 mg by intramuscular injection
Number of subjects: 8
Study: 30547750

Group type: EXPERIMENTAL
Intervention: Intense treatment (four two-weekly standard doses of praziquantel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (one standard dose of praziquantel)
Number of subjects: 0
Study: 26858331

Group type: EXPERIMENTAL
Intervention: High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion Lymph Node Dissection (CLND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLND + High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 0
Study: 26275090

Group type: EXPERIMENTAL
Intervention: NeoSTX-Saline
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: NeoSTX-Bup
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: NeoSTX-Bup-Epi
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bup
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (Saline)
Number of subjects: 84
Study: 23261143

Group type: EXPERIMENTAL
Intervention: CDM
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DEBs
Number of subjects: 122

Group type: COMPARATOR
Intervention: DE
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: CDM and DEBs
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: DE, CDM, DEBs
Number of subjects: 122
Study: 21874932

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + plasma rich in growth factors (PRGF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 6
Study: 19817561

Group type: EXPERIMENTAL
Intervention: Crushing virtual cigarettes
Number of subjects: 91

Group type: COMPARATOR
Intervention: Grasping virtual balls
Number of subjects: 91
Study: 17455733

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (Macugen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15456336

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose prulifloxacin 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study: 11223108

Group type: EXPERIMENTAL
Intervention: Bright white light (2500 lux)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dim red light (50 lux)
Number of subjects: 40
Study: 9237065

Group type: EXPERIMENTAL
Intervention: Occult Blood Bead (OBB) test
Number of subjects: 4970

Group type: EXPERIMENTAL
Intervention: Gastroscopy
Number of subjects: 4970

Group type: COMPARATOR
Intervention: Mass screening (OBB test and gastroscopy)
Number of subjects: 4970
Study: 7643653

Group type: EXPERIMENTAL
Intervention: Laser-cut catheters
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard catheters
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 212
Study: 2527134

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 13
Study: 341739

Group type: EXPERIMENTAL
Intervention: Atenolol 4% eye drops
Number of subjects: 21
Study: 31778265

Group type: EXPERIMENTAL
Intervention: Movement training based on combined brain-machine interfaces and physiotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Initial alpha desynchronization conditions its modulation during intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progressive shift of desynchronization toward the ipsilesional hemisphere
Number of subjects: 30
Study: 31225636

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 29130272

Group type: EXPERIMENTAL
Intervention: Formulary change (addition of a high-potency statin)
Number of subjects: 1100682

Group type: COMPARATOR
Intervention: Guideline change (ACC/AHA cholesterol guidelines)
Number of subjects: 1100682

Group type: EXPERIMENTAL
Intervention: Formulary change (addition of a high-potency atorvastatin)
Number of subjects: 1100682
Study: 25720984

Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 42

Group type: COMPARATOR
Intervention: ProTaper Universal
Number of subjects: 42
Study: 25601294

Group type: EXPERIMENTAL
Intervention: Exposure treatment in three contexts
Number of subjects: 46

Group type: COMPARATOR
Intervention: Exposure treatment in one context
Number of subjects: 46
Study: 23392481

Group type: EXPERIMENTAL
Intervention: 3 rounds of annual mass drug administrations (MDAs) with azithromycin
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Cessation rule for MDA if no infection at 6 or 18 months
Number of subjects: 1600
Study: 20450359

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 15

Group type: COMPARATOR
Intervention: GTR
Number of subjects: 15
Study: 18986393

Group type: EXPERIMENTAL
Intervention: Aortic valve sclerosis (AVS) group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (without AVS)
Number of subjects: 62
Study: 17402204

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) program with initial instruction and 2 reinforcement sessions over 5 years.
Number of subjects: 266064

Group type: COMPARATOR
Intervention: Control group (no BSE instruction).
Number of subjects: 266064

Group type: EXPERIMENTAL
Intervention: BSE group (instruction).
Number of subjects: 266064

Group type: COMPARATOR
Intervention: BSE group and Control group comparison.
Number of subjects: 266064
Study: 12650790

Group type: EXPERIMENTAL
Intervention: Manual air insufflation
Number of subjects: 120

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bowel preparation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Future testing preference
Number of subjects: 120